Nokia Oyj (ADR) (NYSE:NOK) has announced an update for the Nokia 1 which upgrades it to the Android 9 Pie (Go edition). The device has been the last in Nokia’s line-up of phones this year to receive the upgrade to Android 9 Pie. However, with it being updated, all Nokia smartphones are now running the latest Android OS from Google. The update as Nokia explains is part of over 300 security updates that Nokia phones have received over the past two years, making the company one of the more active phone makers when it comes to updating their phones.
Nokia Oyj (ADR) (NYSE:NOK) shares shed -0.99% to finally closed at $4.99 in last active session.
NOK’s distance from 20 day simple moving average is -1.21% and distance from 50-Day simple moving average is -3.62%.
Analyst’s mean target price for NOK is $6.54 while analysts mean recommendation is 2.40. Stock value has moved between $4.71 – 6.65 in last one year. Stock has got OUTPERFORM rating from 4 of Thomson Reuters analysts, 4 given HOLD rating to the stock and 1 given UNDERPERFORM rating. Analyst’s mean target price for NOK is $6.54 while analysts mean recommendation is 2.40.
Nokia Oyj (ADR) (NYSE:NOK) yearly performance is -16.13% and net profit margin is -2.60%. Annual EPS Growth of past 5 years is -28.20%. The current share price indicates that stock is -24.96% away from its one year high and is moving 5.94% ahead of its 52-week low.
On 25 June 2018, Altria Group, Inc. (NYSE:MO) shares advanced 0.60% and ultimately finalized to $48.78 in last traded day. Stock has got OUTPERFORM rating from 3 of Thomson Reuters analysts, 6 given HOLD rating to the stock and 2 given UNDERPERFORM rating. Analyst’s mean target price for MO is $58.73 while analysts mean recommendation is 2.50.
At the movement Halozyme Therapeutics, Inc. (NASDAQ:HALO) is under coverage by number of analysts. Buy rating has been given by 2 analysts to the company stock whereas 1 given UNDERPERFORM rating to stock and 3 given HOLD rating. The consensus recommendation by Thomson Reuters analysts is -0.14 and their mean rating for the stock is 2.60 on scale of 1-5. Analysts mean target price for Halozyme Therapeutics, Inc. (NASDAQ:HALO) is $20.22 while their mean recommendation is 2.60 (1=Buy, 5=sell).
If we look at stock performance in last active day trading, we see that stock has moved advanced 1.06% to end the day at $16.28. The current share price indicate that stock is -13.63% away from its one year high and is moving 22.96% ahead of its 52-week low.